Drug Shows Kidney Response in Lupus Patients
Adults with active lupus nephritis saw kidney improvement in a small early trial, though relapse was common.
Updated on Nov. 6, 2026 in Arthritis

A small phase 2 trial found that daratumumab, a drug that targets plasma cells, was associated with kidney response in six of nine patients with active lupus nephritis at 12 months. The results were presented at the American Society of Nephrology's Kidney Week 2026, and the findings are preliminary given the trial's size.
Why it matters
Lupus nephritis, a kidney complication of lupus, remains difficult to control with standard immunosuppressive therapy, which fails in up to half of patients. An effective, sustained option could change how this complication is managed for people with lupus-related kidney disease, though the current data cannot yet show lasting benefit.
This open-label phase 2 trial enrolled nine patients with active class III, IV, or V lupus nephritis who received 16 subcutaneous doses of daratumumab alongside mycophenolate mofetil over six months. At 12 months, six patients achieved renal response, but four of the six responders relapsed by 24-month follow-up, and the trial had no control group.
The players
American Society of Nephrology
The leading professional organization for kidney specialists, which hosts Kidney Week, the major annual meeting where kidney research such as this trial is presented.
The details
Daratumumab is an anti-CD38 antibody that targets plasma cells, the immune cells that produce the autoantibodies driving lupus. In this trial, patients received the drug over six months alongside an existing immunosuppressant, and kidney measures improved, with median protein leakage in the urine falling sharply and mean kidney filtration rising. Because the trial had no comparison group and so few participants, these gains cannot be attributed to the drug with certainty.
Timeline
At 6 months, the daratumumab dosing course was completed and kidney function improvements were observed.
At 12 months, the primary endpoint of renal response was assessed.
At 24 months, follow-up was completed and relapse was observed in four patients.
Health Landscape
Lupus nephritis treatment has long relied on immunosuppressive drugs that fail in up to half of patients, leaving many at risk of end-stage kidney disease, which affects an estimated 10% to 30% of those with the condition. Targeting plasma cells with daratumumab, a drug originally developed for blood cancers, is an emerging approach that this small trial explores, but it remains at an early stage in the research pipeline.
If you have lupus, a kidney check such as urine protein and kidney filtration testing is a useful thing to raise with your rheumatologist or nephrologist at routine visits. This research is early, so no changes to current treatment follow from it, and any decision about therapy is worth discussing with your doctor.
The takeaway
A promising early signal in lupus-related kidney disease is still far from proven, since the trial was small and relapse was common. Anyone with lupus should keep up regular kidney monitoring and ask their specialist about emerging options as larger studies report.
Further reading
For more on the autoimmune conditions that drive inflammatory joint and organ disease, explore our Arthritis coverage.
Source note: This article includes information reported by Derm Immuno Today.


